Developing onvansertib as Part of a Combination Regimen
Combination therapy is at the center of precision cancer medicine and onvansertib has demonstrated synergy with chemotherapies and targeted therapeutics to potentially enhance the efficacy of, and increase the duration of response to, approved drugs in indications where this is a significant need for new treatment options.
Onvansertib is a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) inhibitor with best-in-class attributes. Onvansertib was developed to have high selectivity for PLK1, only, which is over-expressed in most types of cancer. It has ideal pharmacokinetics – oral administration and a half-life of ~24 hours. Onvansertib has demonstrated synergy in combination with chemotherapies and targeted therapeutics, including Zytiga® (abiraterone acetate)/prednisone, Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib), in in-vitro and in-vivo preclinical models.
Currently, we have three active clinical trials:
A phase 1 trial in solid tumor cancers established the safety and tolerability of onvansertib and identified the recommended Phase 2 dose of 24 mg/m2 (Phase 1 Study).